Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study.

[1]  M. Weichenthal,et al.  The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patients , 2018, The British journal of dermatology.

[2]  M. Weichenthal,et al.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial , 2017, The Lancet.

[3]  R. Advani,et al.  A prospective cohort study of patients with peripheral T‐cell lymphoma in the United States , 2017, Cancer.

[4]  D. Sui,et al.  Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. , 2016, Clinical lymphoma, myeloma & leukemia.

[5]  R. Cowan,et al.  Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Reiniger,et al.  Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides , 2015, Pathology & Oncology Research.

[7]  E. Chang,et al.  Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study. , 2014, JAMA dermatology.

[8]  L. Hughey,et al.  Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. , 2014, Journal of the American Academy of Dermatology.

[9]  B. Coiffier,et al.  Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. , 2012, Clinical lymphoma, myeloma & leukemia.

[10]  R. Willemze,et al.  Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. , 2012, Blood.

[11]  J. Zic,et al.  A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders , 2009, Clinical Cancer Research.

[12]  Angelica Selim,et al.  TNM Classification System for Primary Cutaneous Lymphomas , 2008 .

[13]  M. Duvic,et al.  Treatment of Transformed Mycosis Fungoides with Intermittent Low-Dose Gemcitabine , 2008, Oncology.

[14]  J. Merlio,et al.  Common chromosomal abnormalities in mycosis fungoides transformation , 2007, Genes, chromosomes & cancer.

[15]  L. Thomas,et al.  Transformed mycosis fungoides: clinicopathological features and outcome , 2007, The British journal of dermatology.

[16]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Nicola Pimpinelli,et al.  Defining early mycosis fungoides. , 2005, Journal of the American Academy of Dermatology.

[18]  T. Petrella,et al.  Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. , 2000, Blood.

[19]  R. Kurzrock,et al.  Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. , 1998, Blood.